StayOK - an Innovative Measuring Instrument for the Early Identification and Treatment of Psychosocial Risks

Mental Health Disorder Clinical Trial

— StayOK  

Official title:

StayOK - an Innovative Measuring Instrument for the Early Identification and Treatment of Psychosocial Risks

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03213327
• Other study ID #: BASEC-Nr. 2016-00879
• Status: Completed
• Phase: N/A
• Start date: July 10, 2017
• Est. completion date: July 31, 2019

Study information

• Verified date: June 2020
• Source: Zurich University of Applied Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The validity and the sensitivity of different measures implemented in the web application StayOk are investigated. The measures are used primarily for the assessment and the early identification of psychosocial risks. Secondarily, the results of the assessment are applied to generate health-promoting advices for the user of the web application.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 174
• Est. completion date: July 31, 2019
• Est. primary completion date: July 31, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 16 Years to 65 Years

Eligibility

Inclusion Criteria:

• at 16 years of age

• mild to moderate psychological distress

Exclusion Criteria:

• serious cognitive impairment due to dementia or cerebrovascular insult

• Insufficient knowledge of one of the following languages: German, French, Italian or English

Related Conditions & MeSH terms

• Mental Disorders
• Mental Health Disorder

Intervention

Device:
• StayOk web application
Patients fill in the questionnaires of the web application and receive an analyzed profile of their psychosocial condition and health-promoting advices

Locations

Country	Name	City	State
Switzerland	Helsana	Zürich

Sponsors (6)

Lead Sponsor	Collaborator
Zurich University of Applied Sciences	Design your life, Health and Medical Services, Helsana, Neomentum, Sanatorium Kilchberg AG

Country where clinical trial is conducted

Switzerland, 

References & Publications (3)

Damásio BF, Valentini F, Núñes-Rodriguez SI, Kliem S, Koller SH, Hinz A, Brähler E, Finck C, Zenger M. Is the General Self-Efficacy Scale a Reliable Measure to be used in Cross-Cultural Studies? Results from Brazil, Germany and Colombia. Span J Psychol. 2016 May 26;19:E29. doi: 10.1017/sjp.2016.30. — View Citation

Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med. 1983 Aug;13(3):595-605. — View Citation

Jenny GJ, Bauer GF, Vinje HF, Vogt K, Torp S. The Application of Salutogenesis to Work. 2016 Sep 3. In: Mittelmark MB, Sagy S, Eriksson M, Bauer GF, Pelikan JM, Lindström B, Espnes GA, editors. The Handbook of Salutogenesis [Internet]. Cham (CH): Springer; 2017. Chapter 20. Available from http://www.ncbi.nlm.nih.gov/books/NBK435821/ — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Psychological distress	The psychological distress is assessed by the Brief Symptom Inventory (BSI; Derogatis & Melisaratos, 1983)	0 week (first assessment)
Primary	Work-related sense of coherence	The work-related sense of coherence is assessed by the Work Sense of Coherence (W-SoC 9; Jenny et al., 2016)	0 weeks
Primary	Perceived self-efficacy	This aspect is measure by the General Self-Efficacy Scale (GSE; Damásio et al., 2016)	0 weeks
Secondary	Effectiveness of health-promoting advices	The effectiveness of the advices generated by the software is assessed by means of a self-developed questionnaire: Participants are inquired as to (1) whether they put in practice the advices and (2) how they evaluate the benefit of the applied advices and the consequent satisfaction.	12 weeks after the first assessment

External Links

•   Stay OK